Evaluation and Treatment of Essential and Secondary Hypertension
By:
Claretha Lyas University of Alabama at Birmingham, Birmingham, Alabama

Search for other papers by Claretha Lyas in
Current site
Google Scholar
PubMed Close
and
Rebecca Maxson Auburn University Harrison College of Pharmacy, Birmingham, Alabama

Search for other papers by Rebecca Maxson in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 24: Issue 2
Published Online:
May 2025
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2025 by the American Society of Nephrology 2025
Page Count:
13
Article Category:
Research Article
Print Publication Date:
01 May 2025
Published Online:
May 2025
  • 1.

    Kario K, Okura A, Hoshide S, Mogi M: The WHO global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens Res 47: 1099–1102, 2024 10.1038/s41440-024-01622-w PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Cheung AK, Whelton PK, Muntner P, Schutte AE, Moran AE, Williams B, et al.: International consensus on standardized clinic blood pressure measurement – A call to action. Am J Med 136: 438–445.e1, 2023 10.1016/j.amjmed.2022.12.015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, et al.; SPRINT Research Group: Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 384: 1921–1930, 2021 10.1056/NEJMoa1901281 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al.; BPROAD Research Group: Intensive blood-pressure control in patients with type 2 diabetes. N Engl J Med 392: 1155–1167, 2024 10.1056/NEJMoa2412006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Liu J, Li Y, Ge J, Yan X, Zhang H, Zheng X, et al.; ESPRIT Collaborative Group: Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: An open-label, blinded-outcome, randomised trial. Lancet 404: 245–255, 2024 10.1016/S0140-6736(24)01028-6 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Perloff D, Sokolow M, Cowan R: The prognostic value of ambulatory blood pressures. JAMA 249: 2792–2798, 1983 10.1001/jama.1983.03330440030027 PubMed

  • 7.

    Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al.: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 24: 793–801, 1994 10.1161/01.hyp.24.6.793 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, et al.; Office versus Ambulatory Pressure Study Investigators: Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 348: 2407–2415, 2003 10.1056/NEJMoa022273 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, et al.: Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: Follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation 111: 1777–1783, 2005 10.1161/01.CIR.0000160923.04524.5B PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Huang Q-F, Yang W-Y, Asayama K, Zhang Z-Y, Thijs L, Li Y, et al.: Ambulatory blood pressure monitoring to diagnose and manage hypertension. Hypertension 77: 254–264, 2021 10.1161/HYPERTENSIONAHA.120.14591 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al.: Relationship between clinic and ambulatory blood pressure and mortality: An observational cohort study in 59 124 patients. Lancet 401: 2041–2050, 2023 10.1016/S0140-6736(23)00733-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Mancia G, Facchetti R, Quarti-Trevano F, Grassi G: Reproducibility and treatment effect on office and ambulatory pressure relation. Hypertension 82: 126–135, 2025 10.1161/HYPERTENSIONAHA.124.23549 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al.: 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71: e127–e248, 2018 10.1016/j.jacc.2017.11.006 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Islam SMS, Chow CK, Daryabeygikhotbehsara R, Subedi N, Rawstorn J, Tegegne T, et al.: Wearable cuffless blood pressure monitoring devices: A systematic review and meta-analysis. Eur Heart J Digit Health 3: 323–337, 2022 10.1093/ehjdh/ztac021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Konstantinidis D, Iliakis P, Tatakis F, Thomopoulos K, Dimitriadis K, Tousoulis D, et al.: Wearable blood pressure measurement devices and new approaches in hypertension management: The digital era. J Hum Hypertens 36: 945–951, 2022 10.1038/s41371-022-00675-z PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Beulen BW, Bijnens N, Koutsouridis GG, Brands PJ, Rutten MC, van de Vosse FN: Toward noninvasive blood pressure assessment in arteries by using ultrasound. Ultrasound Med Biol 37: 788–797, 2011 10.1016/j.ultrasmedbio.2011.01.020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Stergiou GS, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, et al.: A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. J Hypertens 36: 472–478, 2018 10.1097/HJH.0000000000001634 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Stergiou GS, Mukkamala R, Avolio A, Kyriakoulis KG, Mieke S, Murray A, et al.; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability: Cuffless blood pressure measuring devices: Review and statement by the European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens 40: 1449–1460, 2022 10.1097/HJH.0000000000003224 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Stergiou GS, Avolio AP, Palatini P, Kyriakoulis KG, Schutte AE, Mieke S, et al.: European Society of Hypertension recommendations for the validation of cuffless blood pressure measuring devices: European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. J Hypertens 41: 2074–2087, 2023 10.1097/HJH.0000000000003483 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Kidney Disease: Improving Global Outcomes Blood Pressure Work G: KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Mar 99: S1–S87, 2021 10.1016/j.kint.2020.11.003 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Bertram S, Bauer F, Shadi R, Seidel M, Doevelaar A, Seibert F, et al.: Prevalence of masked hypertension in attended versus unattended office blood pressure measurement. J Clin Hypertens (Greenwich) 26: 615–623, 2024 10.1111/jch.14798 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Legrand F, Motiejunaite J, Arnoult F, Lahens A, Tabibzadeh N, Robert-Mercier T, et al.: Prevalence and factors associated with masked hypertension in chronic kidney disease. J Hypertens 42: 1000–1008, 2024 10.1097/HJH.0000000000003680 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Georgianos PI, Vaios V, Karligkiotis A, Liakopoulos V: Unmasking hypertension in patients with chronic kidney disease: Who to screen and how to confirm the diagnosis? J Hypertens 42: 1831–1832, 2024 10.1097/HJH.0000000000003814 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Satoh M, Tatsumi Y, Nakayama S, Shinohara Y, Kawazoe M, Nozato Y, et al.: Self-measurement of blood pressure at home using a cuff device for change in blood pressure levels: Systematic review and meta-analysis. Hypertens Res 48: 574–591, 2024 10.1038/s41440-024-01981-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Al-Dalakta A, Tabaja C, Motairek I, El Hajjar AH, Agarwal N, St John J, et al.: Blood pressure time in target range and its impact on clinical outcomes. Curr Cardiol Rep 26: 1145–1151, 2024 10.1007/s11886-024-02111-9 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Buckley LF, Baker WL, Van Tassell BW, Cohen JB, Alkhezi O, Bress AP, et al.: Systolic blood pressure time in target range and major adverse kidney and cardiovascular events. Hypertension 80: 305–313, 2023 10.1161/HYPERTENSIONAHA.122.20141 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Feng Z, Li Y, Wang C, Tian L, Yao S, Wang M, et al.: Combined effect of time in target range and variability of systolic blood pressure on cardiovascular outcomes and mortality in patients with hypertension: A prospective cohort study. J Clin Hypertens (Greenwich) 26: 714–723, 2024 10.1111/jch.14816 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, Kalantar-Zadeh K, et al.: Association of systolic blood pressure variability with mortality, coronary heart disease, stroke, and renal disease. J Am Coll Cardiol 68: 1375–1386, 2016 10.1016/j.jacc.2016.06.054 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Messerli FH, Hofstetter L, Rimoldi SF, Rexhaj E, Bangalore S: Risk factor variability and cardiovascular outcome. J Am Coll Cardiol 73: 2596–2603, 2019 10.1016/j.jacc.2019.02.063 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Parati G, Bilo G, Kollias A, Pengo M, Ochoa JE, Castiglioni P, et al.: Blood pressure variability: Methodological aspects, clinical relevance and practical indications for management – A European Society of Hypertension position paper. J Hypertens 41: 527–544, 2023 10.1097/hjh.0000000000003363 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, et al.: Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens 42: 23–49, 2024 10.1097/hjh.0000000000003563 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Jiang C, Li S, Wang Y, Lai Y, Bai Y, Zhao M, et al.: Diastolic blood pressure and intensive blood pressure control on cognitive outcomes: Insights from the SPRINT MIND trial. Hypertension 80: 580–589, 2023 10.1161/HYPERTENSIONAHA.122.20112 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al.: Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med 385: 2507–2519, 2021 10.1056/NEJMoa2110730 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al.; STOP ACEi Trial Investigators: Renin-angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 387: 2021–2032, 2022 10.1056/NEJMoa2210639 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Desai AS, Webb DJ, Taubel J, Casey S, Cheng Y, Robbie GJ, et al.: Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med 389: 228–238, 2023 10.1056/NEJMoa2208391 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, et al.; KARDIA-1 Study Group: RNA interference with zilebesiran for mild to moderate hypertension: The KARDIA-1 randomized clinical trial. JAMA 331: 740–749, 2024 10.1001/jama.2024.0728 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    ClinicalTrials.gov: Zilebesiran, 2021. Available at: https://clinicaltrials.gov/study/NCT05103332?intr=zilebesiran&checkSpell=&rank=4. Accessed January 3, 2025

  • 38.

    Fulton B, Giri J, Rader F, Cohen DL, Kobayashi T: Renal denervation for hypertension: The current landscape and future directions. Heart Int 18: 5–8, 2024 10.17925/HI.2024.18.1.2 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Kandzari DE, Weber MA, Pathak A, Zidar JP, Saxena M, David SW, et al.: Effect of alcohol-mediated renal denervation on blood pressure in the presence of antihypertensive medications: Primary results from the TARGET BP I randomized clinical trial. Circulation 149: 1875–1884, 2024 10.1161/CIRCULATIONAHA.124.069291 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Ogoyama Y, Abe M, Okamura K, Tada K, Katsurada K, Shibata S, et al.: Effects of renal denervation on blood pressure in patients with hypertension: A latest systematic review and meta-analysis of randomized sham-controlled trials. Hypertens Res 47: 2745–2759, 2024 10.1038/s41440-024-01739-y PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Hu X-R, Liao G-Z, Wang J-W, Ye Y-Y, Chen X-F, Bai L, et al.: Patient-specific factors predicting renal denervation response in patients with hypertension: A systematic review and meta-analysis. J Am Heart Assoc 13: e034915, 2024 10.1161/JAHA.124.034915 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Cluett JL, Blazek O, Brown AL, East C, Ferdinand KC, Fisher NDL, et al.; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on the Kidney in Cardiovascular Disease; and Council on Peripheral Vascular Disease: Renal denervation for the treatment of hypertension: A scientific statement from the American Heart Association. Hypertension 81: e135–e148, 2024 10.1161/HYP.0000000000000240 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Pathak A, Boulestreau R, Sapoval M, Lantelme P, Duly-Bouhanick B, Benamer H, et al.: Catheter-based renal denervation in the treatment of arterial hypertension: An expert consensus statement on behalf of the French Society of Hypertension (SFHTA), French Society of Radiology (SFR), French Society of Interventional Cardiology (GACI), French Society of Cardiology (SFC), French Association of Private Cardiologists (CNCF), French Association of Hospital Cardiologists (CNCH), French Society of Thoracic and Cardiovascular Surgery (SFCTCV) and French Society of Vascular and Endovascular Surgery (SCVE). Arch Cardiovasc Dis 117: 601–611, 2024 10.1016/j.acvd.2024.05.122 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al.: 2023 ESH guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 41: 1874–2071, 2023 10.1097/HJH.0000000000003480 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Blumenthal JA, Hinderliter AL, Smith PJ, Mabe S, Watkins LL, Craighead L, et al.: Effects of lifestyle modification on patients with resistant hypertension: Results of the TRIUMPH randomized clinical trial. Circulation 144: 1212–1226, 2021 10.1161/CIRCULATIONAHA.121.055329 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Freeman MW, Halvorsen Y-D, Marshall W, Pater M, Isaacsohn J, Pearce C, et al.; BrigHTN Investigators: Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 388: 395–405, 2023 10.1056/NEJMoa2213169 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    ClinicalTrial.gov: Baxdrostat, 2021. Available at: https://clinicaltrials.gov/search?intr=baxdrostat. Accessed January 3, 2025

  • 48.

    IPU Inc: Tryvio [Prescribing Information]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf. Accessed January 3, 2025

  • 49.

    Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al.; PRECISION investigators: Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): A multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400: 1927–1937, 2022 10.1016/S0140-6736(22)02034-7 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    de Freminville JB, Amar L, Azizi M, Mallart-Riancho J: Endocrine causes of hypertension: Literature review and practical approach. Hypertens Res 46: 2679–2692, 2023 10.1038/s41440-023-01461-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Zuo R, Liu S, Xu L, Pang H: Key to the treatment of primary aldosteronism in secondary hypertension: Subtype diagnosis. Curr Hypertens Rep 25: 471–480, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al.: The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 101: 1889–1916, 2016 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Wu X, Senanayake R, Goodchild E, Bashari WA, Salsbury J, Cabrera CP, et al.: [11C] metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: A prospective, within-patient trial. Nat Med 29: 190–202, 2023 10.1038/s41591-022-02114-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Suurd DPD, Vorselaars WMCM, Van Beek D-J, Borel Rinkes IHM, Spiering W, Valk GD, et al.: Assessing outcomes after adrenalectomy for primary aldosteronism–early is accurate: Retrospective cohort study. Ann Surg 276: 929–934, 2022 10.1097/SLA.0000000000005639 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Monticone S, Viola A, Rossato D, Veglio F, Reincke M, Gomez-Sanchez C, et al.: Adrenal vein sampling in primary aldosteronism: Towards a standardised protocol. Lancet Diabetes Endocrinol 3: 296–303, 2015 10.1016/S2213-8587(14)70069-5 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Rossi GP, Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM: Effects of mineralocorticoid and AT1 receptor antagonism on the aldosterone-renin ratio in primary aldosteronism—The EMIRA study. J Clin Endocrinol Metab 105: 2060–2067, 2020 10.1210/clinem/dgaa080 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Pintus G, Seccia TM, Amar L, Azizi M, Riester A, Reincke M, et al.: Subtype identification of surgically curable primary aldosteronism during treatment with mineralocorticoid receptor blockade. Hypertension 81: 1391–1399, 2024 10.1161/HYPERTENSIONAHA.124.22721 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al.: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 69: 327–359, 2022 10.1507/endocrj.EJ21-0508 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A: Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 6: 51–59, 2018 10.1016/S2213-8587(17)30367-4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Katsuragawa S, Goto A, Shinoda S, Inoue K, Nakai K, Saito J, et al.: Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism. Hypertension 80: 1909–1920, 2023 10.1161/HYPERTENSIONAHA.123.21096 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Mao M, Feng R, Khan NA, Tao L, Tang P, Zhao Y, et al.: Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: A prospective single-center study. BMC Surg 24: 242, 2024 10.1186/s12893-024-02530-z PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Safian RD, Textor SC: Renal-artery stenosis. N Engl J Med 344: 431–442, 2001 10.1056/NEJM200102083440607 PubMed

  • 63.

    de Mast Q, Beutler JJ: The prevalence of atherosclerotic renal artery stenosis in risk groups: A systematic literature review. J Hypertens 27: 1333–1340, 2009 10.1097/HJH.0b013e328329bbf4 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Hicks CW, Clark TWI, Cooper CJ, de Bhailís ÁM, De Carlo M, Green D, et al.: Atherosclerotic renovascular disease: A KDIGO (Kidney Disease: Improving Global Outcomes) controversies conference. Am J Kidney Dis 79: 289–301, 2022 10.1053/j.ajkd.2021.06.025 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Eirin A, Chade AR, Lerman LO: Kidney intrinsic mechanisms as novel targets in renovascular hypertension. Hypertension 81: 206–217, 2024 10.1161/HYPERTENSIONAHA.123.21362 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Bhalla V, Textor SC, Beckman JA, Casanegra AI, Cooper CJ, Kim ESH, et al.; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Hypertension; Council on Peripheral Vascular Disease; and Council on Cardiovascular Radiology and Intervention: Revascularization for renovascular disease: A scientific statement from the American Heart Association. Hypertension 79: e128–e143, 2022 10.1161/HYP.0000000000000217 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Sarafidis PA, Theodorakopoulou M, Ortiz A, Fernandez-Fernández B, Nistor I, Schmieder R, et al.: Atherosclerotic renovascular disease: A clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). Nephrol Dial Transplant 38: 2835–2850, 2023 10.1093/ndt/gfad095 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    de Bhailis AM, Lake E, Chrysochou C, Green D, Chinnadurai R, Kalra PA: Improving outcomes in atherosclerotic renovascular disease: Importance of clinical presentation and multi-disciplinary review. J Nephrol 37: 1093–1105, 2024 10.1007/s40620-024-01902-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Theodorakopoulou MP, Karagiannidis AG, Ferro CJ, Ortiz A, Sarafidis PA: Renal artery stenting in the correct patients with atherosclerotic renovascular disease: Time for a proper renal and cardiovascular outcome study? Clin Kidney J 16: 201–204, 2023 10.1093/ckj/sfac140 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Cai S, Fu Y, Chen J, Tian M, Li X: Causal relationship between branched-chain amino acids and hypertension: A Mendelian randomization study. J Am Heart Assoc 13: e032084, 2024 10.1161/JAHA.123.032084 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Xu H, Wang X, Geng G, Xu X, Liu L, Zhang Y, et al.: Association of circulating branched-chain amino acids with cardiovascular diseases: A Mendelian randomization study. Nutrients 15: 1580, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Ferreira JP, Gregson J, Bohm M, Rossignol P, Zannad F, Pocock SJ: Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. Clin Cardiol 44: 665–674, 2021 10.1002/clc.23591 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    DeCarolis DD, Gravely A, Olney CM, Ishani A: Impact of antihypertensive drug class on outcomes in SPRINT. Hypertension 79: 1112–1121, 2022 10.1161/HYPERTENSIONAHA.121.18369 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Bansal S, Boucher R, Shen J, Wei G, Chertow GM, Whelton PK, et al.; on behalf of SPRINT: Role of diuretics in cardiovascular events and mortality in systolic blood pressure intervention trial: A post hoc analysis. Clin J Am Soc Nephrol 19: 620–627, 2024 10.2215/CJN.0000000000000406 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, et al.; RADIANCE II Investigators and Collaborators: Endovascular ultrasound renal denervation to treat hypertension: The RADIANCE II randomized clinical trial. JAMA 329: 651–661, 2023 10.1001/jama.2023.0713 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Bloch MJ, Kirtane AJ, Azizi M, Mahfoud F, Basile J, Daemen J, et al.; RADIANCE-HTN Investigators: 36-month durability of ultrasound renal denervation for hypertension resistant to combination therapy in RADIANCE-HTN TRIO. Hypertens Res 47: 3467–3472, 2024 10.1038/s41440-024-01854-w PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77.

    Kirtane AJ, Sharp ASP, Mahfoud F, Fisher NDL, Schmieder RE, Daemen J, et al.; RADIANCE Investigators and Collaborators: Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol 8: 464–473, 2023 10.1001/jamacardio.2023.0338 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, et al.; SPYRAL HTN-ON MED Investigators: Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol 82: 1809–1823, 2023 10.1016/j.jacc.2023.08.045 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Mahfoud F, Kandzari DE, Kario K, Townsend RR, Weber MA, Schmieder RE, et al.: Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet 399: 1401–1410, 2022 10.1016/S0140-6736(22)00455-X PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 80.

    Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, et al.; SYMPLICITY HTN-3 Steering Committee Investigators: Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: Final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet 400: 1405–1416, 2022 10.1016/S0140-6736(22)01787-1 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81.

    Pathak A, Rudolph UM, Saxena M, Zeller T, Müller-Ehmsen J, Lipsic E, et al.: Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention 19: 602–611, 2023 10.4244/EIJ-D-23-00088 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 814 814 766
Full Text Views 132 132 116
PDF Downloads 199 199 167